公开(公告)号：US12048746B2

公开(公告)日：2024-07-30

申请号：US17462654

申请日：2021-08-31

Applicant: SESEN BIO, Inc.

Inventor： Grigorios Zarbis-Papastoitsis ,  Patricia Lowden

IPC: A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  C07K16/24

CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K9/0048 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  C07K16/248 ,  C07K2317/94

Abstract: Featured herein are pharmaceutical compositions and formulations containing an interleukin-6 (IL-6) antagonist, e.g., an IL-6 antibody molecule, designed for administration for a subject. The pharmaceutical compositions and formulations provided herein are suitable for use in manufacture of medicaments or methods of treating subjects with IL-6 associated diseases, e.g., ocular diseases associated with elevated levels of IL-6.

公开(公告)号：US12048693B2

公开(公告)日：2024-07-30

申请号：US16959954

申请日：2019-01-04

Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique ,  Université Côte d'Azur

Inventor： Thierry Passeron ,  Rachid Benhida ,  Pascal Dao ,  Gian Marco De Donatis ,  Anthony Martin

IPC: A61K31/4706 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07D215/44 ,  C07K16/28

CPC classification number: A61K31/4706 ,  A61K39/3955 ,  A61P35/00 ,  A61P35/04 ,  C07D215/44 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827

Abstract: The present invention relates to a compound of general formula (I), wherein R1 is OCH2CH2OCH3 or OCH3, R′1 is H or OH, R2 is Cl, F, Br or I, with the proviso that when: R1 is OCH2CH2OCH3 then R′1 is H, R1 is OCH3 then R′1 is OH, its pharmaceutically acceptable salts and/or optical isomers, tautomers, solvates or isotopic variations thereof. The invention also relates to said compounds for use in the treatment of cancer, namely solid tumor cancer, and preferably those selected from melanoma, colon, lung, pancreas, kidney, Merkel carcinoma, squamous cell carcinoma, prostate, breast and bladder. The invention also relates to a pharmaceutical composition comprising said compounds.

公开(公告)号：US20240247060A1

公开(公告)日：2024-07-25

申请号：US18575581

申请日：2022-07-13

Applicant: SANYOU BIOPHARMACEUTICALS CO., LTD.

Inventor： Xintian YAN ,  Guojun LANG ,  Yongcong TAN ,  Chanjuan LIU ,  Chao KONG ,  Run YAN ,  Yaru LIU ,  Tianen YAO

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K47/6849 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: The present invention relates to specific CLDN18.2 binding molecules, and an immunoconjugate and a composition containing the CLDN18.2 binding molecules. The present invention further relates to a nucleic acid encoding the CLDN18.2 binding molecules, a host cell containing same, and a method for preparing the CLDN18.2 binding molecules. Furthermore, the present invention relates to the therapeutic and diagnostic use of the CLDN18.2 binding molecules. In particular, the present invention relates to the combined treatment of the CLDN18.2 binding molecules with other therapies, such as a therapeutic method or a therapeutic agent.

公开(公告)号：US12042485B2

公开(公告)日：2024-07-23

申请号：US17872783

申请日：2022-07-25

Applicant: MEDICINOVA, INC.

Inventor： Kazuko Matsuda ,  Federico Carlos Aréjola Gaeta

IPC: A61K31/437 ,  A61K31/138 ,  A61K31/167 ,  A61K31/19 ,  A61K31/404 ,  A61K31/47 ,  A61K31/495 ,  A61K31/655 ,  A61K33/243 ,  A61K38/21 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/437 ,  A61K31/138 ,  A61K31/167 ,  A61K31/19 ,  A61K31/404 ,  A61K31/47 ,  A61K31/495 ,  A61K31/655 ,  A61K33/243 ,  A61K38/212 ,  A61K39/3955 ,  A61P35/00

Abstract: A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

公开(公告)号：US20240239909A1

公开(公告)日：2024-07-18

申请号：US18441998

申请日：2024-02-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, JR. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P37/00 ,  C07K16/46 ,  C12N15/63 ,  A61K39/00 ,  A61K45/06 ,  C07K14/705

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K47/68 ,  A61K47/6849 ,  A61P37/00 ,  C07K16/468 ,  C12N15/63 ,  A61K2039/505 ,  A61K45/06 ,  A61K47/6803 ,  C07K14/70578 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20240239907A1

公开(公告)日：2024-07-18

申请号：US18563720

申请日：2022-05-25

Applicant: Edelweiss Immune Inc

Inventor： Lifei Hou ,  Eileen Remold-O'Donnell

IPC: C07K16/28 ,  A61K31/137 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K39/395 ,  A61K47/68 ,  A61K49/00

CPC classification number: C07K16/2866 ,  A61K31/137 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K39/3955 ,  A61K47/6849 ,  A61K49/0002 ,  C07K2317/622 ,  C07K2319/30

Abstract: The invention provides, in various embodiments, polypeptides that specifically bind to C-X-C Motif Chemokine Receptor 6 (CXCR6) (e.g., human CXCR6). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and compositions and methods for treating, diagnosing, and/or prognosing diseases or disorders (e.g., diseases of the immune system or cancer).

公开(公告)号：US20240239882A1

公开(公告)日：2024-07-18

申请号：US18392926

申请日：2023-12-21

Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG

Inventor： Jörg WISCHHUSEN ,  Markus JUNKER ,  Thomas MÜLLER ,  Stefan SAREMBA

IPC: C07K16/22 ,  A61K45/06 ,  A61K39/00 ,  A61K39/395

CPC classification number: C07K16/22 ,  A61K45/06 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.

公开(公告)号：US20240238623A9

公开(公告)日：2024-07-18

申请号：US17812264

申请日：2022-07-13

Applicant: ImmunityBio, Inc.

Inventor： Laurent H. Boissel ,  Hans G. Klingemann

IPC: A61K35/17 ,  A61K35/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K35/28 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K16/10 ,  C07K16/1018 ,  C07K16/1027 ,  C07K16/1063 ,  C07K16/109 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcϵRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.

公开(公告)号：US20240238376A1

公开(公告)日：2024-07-18

申请号：US18562108

申请日：2022-05-23

Applicant: Novartis AG

Inventor： Matthias Klaus SCHIEKER ,  Celeste SCOTTI

IPC: A61K38/18 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61P19/02 ,  C07K16/24

CPC classification number: A61K38/1891 ,  A61K9/0019 ,  A61K39/3955 ,  A61P19/02 ,  C07K16/245 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/76

Abstract: Provided herein are methods and dosage regimens for the treatment of osteoarthritis (e.g., knee osteoarthritis). These methods and dosage regimens include intra-articular injections of Compound 1 alone, or in combination with an anti-inflammatory antibody (e.g., an anti-IL-10 antibody).

公开(公告)号：US20240238214A1

公开(公告)日：2024-07-18

申请号：US18580977

申请日：2022-07-20

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Soonbum Kwon

IPC: A61K9/51 ,  A61K31/337 ,  A61K38/07 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K9/5146 ,  A61K9/5123 ,  A61K9/5169 ,  A61K31/337 ,  A61K38/07 ,  A61K39/3955 ,  A61P35/00

Abstract: Nanoconstructs and compositions comprising a nanoparticle coated with an immunoadjuvant (e.g. ATP) and comprising one or more therapeutic agents (e.g. ICD inducer) encapsulated therein; and methods for treating cancer in a subject using such nanoconstructs and compositions, as well as combination immunotherapies.